Bericht
Patent analysis for medicines and biotherapeutics in trials to treat COVID-19
This report provides an analysis of patents covering medicines in trials to treat COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent applications. The medicines considered for the patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the biotherapeutics tocilizumab, siltuximab and sarilumab.
- Sprache
-
Englisch
- Erschienen in
-
Series: Research Paper ; No. 153
- Klassifikation
-
Sozialwissenschaften, Soziologie, Anthropologie
- Thema
-
Access to Medicines
Affordable Medicines
Biotherapeutics
Coronavirus
COVID-19
Favipiravir
Global Health
Health
Intellectual Property
Molnupiravir
Nirmatrelvir
Pandemic
Patent
Patent Offices
Public Health
Remdesivir
Ruxolitinib
Sarilumab
Siltuximab
Tocilizumab
- Ereignis
-
Geistige Schöpfung
- (wer)
-
Ravi, Srividya
- Ereignis
-
Veröffentlichung
- (wer)
-
South Centre
- (wo)
-
Geneva
- (wann)
-
2022
- Handle
- Letzte Aktualisierung
-
10.03.2025, 11:44 MEZ
Datenpartner
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Bericht
Beteiligte
- Ravi, Srividya
- South Centre
Entstanden
- 2022